Aclaris Therapeutics Inc

Evercore ISI says this biotech stock is a high risk, high reward play, with more than 200% upside

October 3, 2023

[ad_1] Evercore ISI initiated coverage of Aclaris Therapeutics , a clinical stage biotech working on immunology and inflammation drugs, at…